Irish medtech business Aerogen is Ireland’s largest indigenous medtech business and a global leader in acute care aerosol drug delivery.
Galway-headquartered medtech business Aerogen is embarking on a €300m Enterprise Ireland-supported transformational scaling and investment plan, which will result in the creation of 725 new jobs in Ireland over the next 10 years.
Founded by John Power as Cerus Medical in 1997, Galway-headquartered Aerogen’s acute care aerosol drug delivery devices are used in 75 countries and by more than 20m patients worldwide. Customers include 80pc of hospitals in Ireland and 60pc of the top hospitals in the US.
“We just reached the pivotal milestone of having treated our 25th millionth patient, and we will continue to innovate across the respiratory journey for patients from our HQ here in Galway”
ThinkBusiness reported in July how the business is about to embark on its biggest bet yet: a vital drug that will help prevent fatalities among newborn babies.
A powerful force in Irish medtech
With over 25 years of experience, 300 international patents and over 200 clinical papers, Aerogen technology has been used to treat over 25 million patients in emergency departments, adult and paediatric ICUs, general wards and ambulance services in 75 countries worldwide. Aerogen offers a safe and powerful drug delivery device for the treatment of critical respiratory illness and other non-respiratory illnesses and is the leading manufacturer of high performance, single-use, respiratory nebulisers in the world.
The Aerogen Group is headquartered in Dangan, Galway and the new Irish jobs will be across R&D, manufacturing, science and engineering and located there and at its two manufacturing sites in Parkmore, Galway and in Shannon. The implementation of the transformational scaling plan will enable Aerogen to create up to 725 highly skilled jobs in the West by 2035 increasing its global workforce to over 2,000 of which over 1,100 will be based in Ireland.
As part of the ten-year scaling and investment plan, Aerogen aims to accelerate its existing device technology through new product innovation and leveraging of global opportunities. Simultaneously it will build its emerging biopharmaceutics business with a major breakthrough in treating premature newborns with Infant Respiratory Stress Syndrome. High quality R&D is crucial to its goal to become a global leader in pulmonary medicine and biopharmaceutics delivery, combined with a true commitment to improving patient care through cutting-edge technologies.
Aerogen has been growing at over 20% per annum for the last decade with annual revenues now over €150 million and has contributed €130 million to local Irish businesses in the time. Over the next five years Aerogen expects to contribute a further €250 million in income and corporation taxes, directly benefiting the Irish economy.
“We are delighted to announce this continued expansion of Aerogen as a truly global life science company,” said John Power, CEO and Founder of Aerogen.
“Enterprise Ireland have been a superb partner in supporting this journey on which we just reached the pivotal milestone of having treated our 25th millionth patient, and we will continue to innovate across the respiratory journey for patients from our HQ here in Galway.”
The expansion is supported by Enterprise Ireland, who welcome the creation of high value jobs and the strengthening of Ireland’s position in the global value chain of medical technology and manufacturing.
This morning (15 January 2025), Enterprise Ireland revealed its end of year results for 2024, confirming that total employment at companies supported by the agency increased to a record 234,454 last year, with 15,741 new jobs created. 64% of the new jobs created in these client companies were located outside the Dublin region with all nine regions recording jobs growth.
“The Government through Enterprise Ireland is targeting ambitious scaling of Irish multinationals that will help drive the Irish economy and our competitive advantage forward,” said Minister for Enterprise, Trade and Employment Peter Burke, TD.
“Aerogen’s announcement today is evidence of that Irish multinational ambition in action, and we are delighted to support them on their patient-focused mission.”
Main image at top: John Power, founder and CEO of Aerogen
-
Bank of Ireland is welcoming new customers every day – funding investments, working capital and expansions across multiple sectors. To learn more, click here
-
Listen to the ThinkBusiness Podcast for business insights and inspiration. All episodes are here. You can also listen to the Podcast on:
-
Spotify
-
SoundCloud
-
Apple
